Erik J Tillman

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2021
Publications (10 Years): 4

Top Topics

Endoplasmic Reticulum

Transcription Factor

Candida Albicans

Top Venues

Nature medicine

British journal of pharmacology

Akero Therapeutics

Massachusetts Institute of Technology (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Akero Therapeutics

United States

Sr Scientist, Assoc Dir Scientific Strategy

Dana Farber Cancer Institute

United States

Research Technician :: Pediatric Oncology

Education History

Massachusetts Institute of Technology

United States

PHD :: Biology

Publications

Erik J Tillman, William J Brock, Tim Rolph
Efruxifermin, a long-acting Fc-fusion FGF21 analogue, reduces body weight gain but does not increase sympathetic tone or urine volume in Sprague Dawley rats. British journal of pharmacology (2021)
Stephen A Harrison, Peter J Ruane, Bradley L Freilich, Guy Neff, Rashmee Patil, Cynthia A Behling, Chen Hu, Erica Fong, Brittany de Temple, Erik J Tillman, Timothy P Rolph, Andrew Cheng, Kitty Yale
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial. Nature medicine 27 (7) (2021)
Marissa Fletcher, Erik J Tillman, Vincent L Butty, Stuart S Levine, Dennis H Kim
Global transcriptional regulation of innate immunity by ATF-7 in C. elegans. PLoS genetics 15 (2) (2019)
Erik J Tillman, Claire E Richardson, Douglas J Cattie, Kirthi C Reddy, Nicolas J Lehrbach, Rita Droste, Gary Ruvkun, Dennis H Kim
Endoplasmic Reticulum Homeostasis Is Modulated by the Forkhead Transcription Factor FKH-9 During Infection of Caenorhabditis elegans. Genetics 210 (4) (2018)